Oral mizoribine pulse therapy for steroid-dependent focal segmental glomerulosclerosis.
A 24-year-old woman with focal segmental glomerulosclerosis was referred to our hospital for treatment of nephrotic syndrome. Though she experienced partial remission following treatment with prednisone and cyclosporine, she had a relapse of nephrotic syndrome when her prednisone was tapered off to 30 mg/day. The prednisone could not be tapered to less than 30 mg/day due to repeated relapses. After introduction of oral mizoribine (MZR) pulse therapy, the patient's prednisone was tapered to 15 mg/day and she had no signs of relapse for more than 1 year. This case suggests that oral MZR pulse therapy is a good therapeutic option for patients with steroid-dependent nephrotic syndrome.
Doi
T
T
Department of Nephrology, Graduate School of Biomedical Sciences, Hiroshima University, Hiroshima, Japan.
Masaki
T
T
Shiraki
N
N
Kawai
T
T
Yorioka
N
N
D000284:Administration, Oral; D000328:Adult; D001781:Blood Component Removal; D003131:Combined Modality Therapy; D016572:Cyclosporine / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D005260:Female; D005923:Glomerulosclerosis, Focal Segmental / Q000188:drug therapy* / Q000628:therapy; D005938:Glucocorticoids / Q000627:therapeutic use; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage*; D009404:Nephrotic Syndrome / Q000188:drug therapy / Q000628:therapy; D011241:Prednisone / Q000627:therapeutic use; D020551:Pulse Therapy, Drug; D012263:Ribonucleosides / Q000008:administration & dosage*
D005938:Glucocorticoids; D007166:Immunosuppressive Agents; D012263:Ribonucleosides; C010052:mizoribine; D016572:Cyclosporine; D011241:Prednisone